Soleus Capital, a private equity company, led a $96m Series B funding round in Antios Therapeutics, a clinical-stage biopharmaceutical company. Additional investors included RA Capital Management, Adage Capital Management, Pontifax Capital, Aisling Capital, Altium Capital, Amzak Health, Granite Point Capital Management, LP First Capital, LifeSci Venture, Lumira Ventures, CAM Capital, Delos Capital, Domain Associates and Sixty Degree Capital. “Despite significant progress in recent years, HBV remains an area of high unmet medical need. Given the mechanistic rationale and impressive early data, we believe ATI-2173 could play an essential role in developing curative regimens for the millions of people suffering from chronic HBV infection. We are excited to partner with the experienced team at Antios to help bring this therapy to patients,” Guy Levy, Soleus Capital Chief Investment Officer.